> Back to seminars list

Seminar

Monday, April 15th, 2019
14h
Centre de Recherche - Paris - Amphithéâtre Constant-Burg - 12 rue Lhomond, Paris 5e

Targeted Antisense Therapeutics for Modulation of Splicing or NMD

 

 

Pr. Adrian KRAINER has made huge contributions to our understanding of splicing factors and their role in regulating alternative splicing. In a culmination of this success, he has identified ways to control alternative splicing patterns in order to correct defective gene expression in individuals with spinal muscular atrophy (SMA). The FDA has approved Spinraza, an antisense oligonucleotide that directs productive splicing in individuals with SMA, resulting in the first effective treatment for individuals with this disease. Spinraza is one of the first RNA therapeutics ever. In recognition of these advancements, he and his collaborator, C. Frank Bennett from Ionis Pharmaceuticals, have been awarded the 2019 Breakthrough Prize in Life Sciences.

Adrian holds the St. Giles Foundation Professorship at Cold Spring Harbor Laboratory where he has worked since 1986 as a postdoctoral researcher and then as a faculty member. He has authored over 100 research articles and is an inventor on over 100 patents and patent applications. Adrian served as the President of the RNA Society in 2014, and was awarded the RNA Society’s 2019 Lifetime Achievement Award.

Event poster

Speaker(s)

Prof. Adrian Krainer
Prof.

Cold Spring Harbor Laboratory, Long Island, NY, USA

Hosted by

Unit Training

Invited by

Stéphan Vagner
Domain 1 - UMR 3348 - Genotoxic Stress and Cancer

Institut Curie

Martin Dutertre
Domain 1 - UMR 3348 - Genotoxic Stress and Cancer

Institut Curie

Contact

Stéphan Vagner

Institut Curie

Send an e-mail

Unit Training

Send an e-mail

Martin Dutertre

Institut Curie

Send an e-mail

Virginie Bel

Send an e-mail